Related coverage linked through entity extraction aliases.
Jul 16, 2026
FDA approved roflumilast cream 0.3% (Zoryve) for plaque psoriasis in children age 2+, the first once-daily steroid-free topical for that group. A meta-analysis found it improved IGA scores and was well tolerated.
Jul 31, 2026
A botanical moisturizer with oat and aloe outperformed metronidazole for rosacea erythema and lesions over 12 weeks. A separate study found nine risk factors for rosacea severity, including female sex, family history, and skin care habits.
May 07, 2026
argenx reported $1.3B in Q1 2026 global product net sales (63% YoY growth). The FDA PDUFA target date for seronegative gMG is May 10, 2026. Positive ADAPT OCULUS results support an oMG label expansion. Pipeline milestones include myositis readout in Q3 2026 and MMN readout in Q4 2026.
Mar 16, 2026
Two phase 3 trials demonstrate significant improvements in skin clearance and disease severity for children and adolescents with moderate-to-severe atopic dermatitis treated with targeted biologics.
Feb 13, 2026
Novartis announced final Phase III ALIGN results showing Vanrafia slowed kidney function decline in adults with IgA nephropathy, supporting planned submissions for traditional approval in 2026 following accelerated approvals in the U.S. and China in 2025.
